Gilead
Coverage of Gilead in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
President Trump plans to impose 100% tariffs on imported generic medicines starting in August 2028, increasing to 200% in 2029, aiming to bring pharmaceutical manufacturing to the U.S. Critics warn this could raise drug costs, cause shortages, and disrupt supply chains. Indian drugmakers, a major U.S. generic drug supplier, have been unsettled by the proposal.
- Virginians living with HIV struggle to get drugs that fight the virus after massive health care cuts
Virginia's health department cut funding for HIV clinics, leading to patients struggling to access antiretroviral medications. Nonprofit providers report insufficient state budget restoration, with clinics overwhelmed as clients near medication shortages.
- Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people
Gilead's HIV drug lenacapavir has the potential to transform HIV treatment, but the company is preventing millions of low-income patients from accessing it. The article criticizes the pharmaceutical company for prioritizing profit over equitable distribution.